Novartis is seeking an order blocking Eugia’s generic version of the oral chemotherapy treatment until the patents have expired, and cash compensation if it makes copies before then, according to a complaint filed June 27 in the US District Court for the District of Delaware. The patents cover the composition and use of the pharmaceutical compound nilotinib—specifically, its various forms and methods of treating certain types of cancer.
US Patent No. 9,061,029 , which expires in ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.